Strategies for switching antipsychotics

Explain to the doctor that there is a potential for relapse with any switching strategy and no method has been proven to be superior to another. Still, if relapse is a concern, the delayed withdrawal method is reasonable in theory. Suggest starting risperidone at 1 mg twice daily for one week, follo...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Canadian pharmacists journal 2006-01, Vol.139 (1), p.51
1. Verfasser: De Jong, Mandy
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue 1
container_start_page 51
container_title Canadian pharmacists journal
container_volume 139
creator De Jong, Mandy
description Explain to the doctor that there is a potential for relapse with any switching strategy and no method has been proven to be superior to another. Still, if relapse is a concern, the delayed withdrawal method is reasonable in theory. Suggest starting risperidone at 1 mg twice daily for one week, followed by 2 mg twice daily for one week, and then increasing to 3 mg twice daily, which is a reasonable initial target dose. After risperidone has been maintained at the target dose for one week, the olanzapine can be tapered by 5 mg weekly (i.e., decrease to 10 mg daily for one week, then 5 mg daily for one week) before being discontinued. Explain to [Jason] that risperidone is less likely to cause weight gain than olanzapine,8 but that he should still monitor his weight closely; emphasize the importance of healthy eating and exercise. Monitoring for side effects like extrapyramidal symptoms and drowsiness while on both medications is also advisable. Jason should be told about the potential for exacerbation of psychotic symptoms, and should also be given explicit instructions with respect to the medication switch process to prevent any errors.4 The primary reasons for switching antipsychotic drug therapy are lack of efficacy or presence of adverse effects.3 Lack of efficacy may manifest as persistent positive symptoms (e.g., delusions, hallucinations) or residual negative symptoms (e.g., flattened affect, anhedonia).4" Unresponsive cognitive symptoms (e.g., impaired attention or memory) or depressive symptoms may also be important factors when considering a medication switch.4 Side effects that may necessitate switching antipsychotics include extrapyramidal symptoms, anticholinergic effects, tardive dyskinesia, weight gain, sedation, and hyperprolactinemia (which can result in amenorrhea, gynecomastia, and sexual dysfunction).4,5
doi_str_mv 10.1177/171516350613900113
format Article
fullrecord <record><control><sourceid>proquest</sourceid><recordid>TN_cdi_proquest_journals_221199865</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1197079921</sourcerecordid><originalsourceid>FETCH-LOGICAL-p97t-144d56caf6be219795b04bb6492fdf0b28f6b9dd9f77543d0c9f6390478ded3</originalsourceid><addsrcrecordid>eNotjk1Lw0AYhBdRsFb_gKfgxVP0ffcz71GKVqFQqB68lexXu0WSmN0i_nsjepqBeZgZxq4R7hCNuUeDCrVQoFEQAKI4YTMkFLUBfD-d_ATUv8Q5u8j5ACClhGbGbl_L2JawSyFXsR-r_JWK26duV7VdSUP-dvu-JJcv2VlsP3K4-tc52zw9vi2e69V6-bJ4WNUDmVKjlF5p10ZtA0cypCxIa7UkHn0Ey5spIe8pGqOk8OAo6umwNI0PXszZzV_pMPafx5DL9tAfx27a23KOSNRoJX4AlZVCTQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>221199865</pqid></control><display><type>article</type><title>Strategies for switching antipsychotics</title><source>SAGE Complete</source><creator>De Jong, Mandy</creator><creatorcontrib>De Jong, Mandy</creatorcontrib><description>Explain to the doctor that there is a potential for relapse with any switching strategy and no method has been proven to be superior to another. Still, if relapse is a concern, the delayed withdrawal method is reasonable in theory. Suggest starting risperidone at 1 mg twice daily for one week, followed by 2 mg twice daily for one week, and then increasing to 3 mg twice daily, which is a reasonable initial target dose. After risperidone has been maintained at the target dose for one week, the olanzapine can be tapered by 5 mg weekly (i.e., decrease to 10 mg daily for one week, then 5 mg daily for one week) before being discontinued. Explain to [Jason] that risperidone is less likely to cause weight gain than olanzapine,8 but that he should still monitor his weight closely; emphasize the importance of healthy eating and exercise. Monitoring for side effects like extrapyramidal symptoms and drowsiness while on both medications is also advisable. Jason should be told about the potential for exacerbation of psychotic symptoms, and should also be given explicit instructions with respect to the medication switch process to prevent any errors.4 The primary reasons for switching antipsychotic drug therapy are lack of efficacy or presence of adverse effects.3 Lack of efficacy may manifest as persistent positive symptoms (e.g., delusions, hallucinations) or residual negative symptoms (e.g., flattened affect, anhedonia).4" Unresponsive cognitive symptoms (e.g., impaired attention or memory) or depressive symptoms may also be important factors when considering a medication switch.4 Side effects that may necessitate switching antipsychotics include extrapyramidal symptoms, anticholinergic effects, tardive dyskinesia, weight gain, sedation, and hyperprolactinemia (which can result in amenorrhea, gynecomastia, and sexual dysfunction).4,5</description><identifier>ISSN: 1715-1635</identifier><identifier>EISSN: 1913-701X</identifier><identifier>DOI: 10.1177/171516350613900113</identifier><language>eng</language><publisher>SAGE PUBLICATIONS, INC</publisher><subject>Antipsychotics ; Drug therapy ; Guidelines ; Mental disorders ; Pharmacists ; Risk assessment ; Tranquilizers</subject><ispartof>Canadian pharmacists journal, 2006-01, Vol.139 (1), p.51</ispartof><rights>Copyright Keith Health Care Communications Jan/Feb 2006</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids></links><search><creatorcontrib>De Jong, Mandy</creatorcontrib><title>Strategies for switching antipsychotics</title><title>Canadian pharmacists journal</title><description>Explain to the doctor that there is a potential for relapse with any switching strategy and no method has been proven to be superior to another. Still, if relapse is a concern, the delayed withdrawal method is reasonable in theory. Suggest starting risperidone at 1 mg twice daily for one week, followed by 2 mg twice daily for one week, and then increasing to 3 mg twice daily, which is a reasonable initial target dose. After risperidone has been maintained at the target dose for one week, the olanzapine can be tapered by 5 mg weekly (i.e., decrease to 10 mg daily for one week, then 5 mg daily for one week) before being discontinued. Explain to [Jason] that risperidone is less likely to cause weight gain than olanzapine,8 but that he should still monitor his weight closely; emphasize the importance of healthy eating and exercise. Monitoring for side effects like extrapyramidal symptoms and drowsiness while on both medications is also advisable. Jason should be told about the potential for exacerbation of psychotic symptoms, and should also be given explicit instructions with respect to the medication switch process to prevent any errors.4 The primary reasons for switching antipsychotic drug therapy are lack of efficacy or presence of adverse effects.3 Lack of efficacy may manifest as persistent positive symptoms (e.g., delusions, hallucinations) or residual negative symptoms (e.g., flattened affect, anhedonia).4" Unresponsive cognitive symptoms (e.g., impaired attention or memory) or depressive symptoms may also be important factors when considering a medication switch.4 Side effects that may necessitate switching antipsychotics include extrapyramidal symptoms, anticholinergic effects, tardive dyskinesia, weight gain, sedation, and hyperprolactinemia (which can result in amenorrhea, gynecomastia, and sexual dysfunction).4,5</description><subject>Antipsychotics</subject><subject>Drug therapy</subject><subject>Guidelines</subject><subject>Mental disorders</subject><subject>Pharmacists</subject><subject>Risk assessment</subject><subject>Tranquilizers</subject><issn>1715-1635</issn><issn>1913-701X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2006</creationdate><recordtype>article</recordtype><sourceid>BENPR</sourceid><recordid>eNotjk1Lw0AYhBdRsFb_gKfgxVP0ffcz71GKVqFQqB68lexXu0WSmN0i_nsjepqBeZgZxq4R7hCNuUeDCrVQoFEQAKI4YTMkFLUBfD-d_ATUv8Q5u8j5ACClhGbGbl_L2JawSyFXsR-r_JWK26duV7VdSUP-dvu-JJcv2VlsP3K4-tc52zw9vi2e69V6-bJ4WNUDmVKjlF5p10ZtA0cypCxIa7UkHn0Ey5spIe8pGqOk8OAo6umwNI0PXszZzV_pMPafx5DL9tAfx27a23KOSNRoJX4AlZVCTQ</recordid><startdate>20060101</startdate><enddate>20060101</enddate><creator>De Jong, Mandy</creator><general>SAGE PUBLICATIONS, INC</general><scope>3V.</scope><scope>7RV</scope><scope>7XB</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8FQ</scope><scope>8FV</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>KB0</scope><scope>M3G</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope></search><sort><creationdate>20060101</creationdate><title>Strategies for switching antipsychotics</title><author>De Jong, Mandy</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p97t-144d56caf6be219795b04bb6492fdf0b28f6b9dd9f77543d0c9f6390478ded3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2006</creationdate><topic>Antipsychotics</topic><topic>Drug therapy</topic><topic>Guidelines</topic><topic>Mental disorders</topic><topic>Pharmacists</topic><topic>Risk assessment</topic><topic>Tranquilizers</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>De Jong, Mandy</creatorcontrib><collection>ProQuest Central (Corporate)</collection><collection>Nursing &amp; Allied Health Database</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Canadian Business &amp; Current Affairs Database</collection><collection>Canadian Business &amp; Current Affairs Database (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>Nursing &amp; Allied Health Database (Alumni Edition)</collection><collection>CBCA Reference &amp; Current Events</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><jtitle>Canadian pharmacists journal</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>De Jong, Mandy</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Strategies for switching antipsychotics</atitle><jtitle>Canadian pharmacists journal</jtitle><date>2006-01-01</date><risdate>2006</risdate><volume>139</volume><issue>1</issue><spage>51</spage><pages>51-</pages><issn>1715-1635</issn><eissn>1913-701X</eissn><abstract>Explain to the doctor that there is a potential for relapse with any switching strategy and no method has been proven to be superior to another. Still, if relapse is a concern, the delayed withdrawal method is reasonable in theory. Suggest starting risperidone at 1 mg twice daily for one week, followed by 2 mg twice daily for one week, and then increasing to 3 mg twice daily, which is a reasonable initial target dose. After risperidone has been maintained at the target dose for one week, the olanzapine can be tapered by 5 mg weekly (i.e., decrease to 10 mg daily for one week, then 5 mg daily for one week) before being discontinued. Explain to [Jason] that risperidone is less likely to cause weight gain than olanzapine,8 but that he should still monitor his weight closely; emphasize the importance of healthy eating and exercise. Monitoring for side effects like extrapyramidal symptoms and drowsiness while on both medications is also advisable. Jason should be told about the potential for exacerbation of psychotic symptoms, and should also be given explicit instructions with respect to the medication switch process to prevent any errors.4 The primary reasons for switching antipsychotic drug therapy are lack of efficacy or presence of adverse effects.3 Lack of efficacy may manifest as persistent positive symptoms (e.g., delusions, hallucinations) or residual negative symptoms (e.g., flattened affect, anhedonia).4" Unresponsive cognitive symptoms (e.g., impaired attention or memory) or depressive symptoms may also be important factors when considering a medication switch.4 Side effects that may necessitate switching antipsychotics include extrapyramidal symptoms, anticholinergic effects, tardive dyskinesia, weight gain, sedation, and hyperprolactinemia (which can result in amenorrhea, gynecomastia, and sexual dysfunction).4,5</abstract><pub>SAGE PUBLICATIONS, INC</pub><doi>10.1177/171516350613900113</doi></addata></record>
fulltext fulltext
identifier ISSN: 1715-1635
ispartof Canadian pharmacists journal, 2006-01, Vol.139 (1), p.51
issn 1715-1635
1913-701X
language eng
recordid cdi_proquest_journals_221199865
source SAGE Complete
subjects Antipsychotics
Drug therapy
Guidelines
Mental disorders
Pharmacists
Risk assessment
Tranquilizers
title Strategies for switching antipsychotics
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-10T23%3A25%3A02IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Strategies%20for%20switching%20antipsychotics&rft.jtitle=Canadian%20pharmacists%20journal&rft.au=De%20Jong,%20Mandy&rft.date=2006-01-01&rft.volume=139&rft.issue=1&rft.spage=51&rft.pages=51-&rft.issn=1715-1635&rft.eissn=1913-701X&rft_id=info:doi/10.1177/171516350613900113&rft_dat=%3Cproquest%3E1197079921%3C/proquest%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=221199865&rft_id=info:pmid/&rfr_iscdi=true